Provectus Pharmaceuticals

Provectus Pharmaceuticals (nyse: PVCT) is a pharmaceutical firm involved in the pursuit of new cancer treatments, including those for breast cancer, liver cancer, and metastatic melanoma. In addition, Provectus has entered stage II clinical trials for a new topical psoriasis treatment.

Their development pipeline includes Provecta, an agent that trials have shown to be "retained in tumor cells while leaving normal tissue unharmed, thereby killing the tumor cells and sparing healthy tissue." Provecta has also shown to produce what is called the "bystander effect" which is when the drug is used to kill a tumor, other untreated tumors also disappear.